These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15119286)

  • 1. Third line anti-HIV therapy options.
    Proj Inf Perspect; 2004 Jan; (37):19-21. PubMed ID: 15119286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for third line therapy.
    Proj Inf Perspect; 2002 Mar; (34):8-9. PubMed ID: 12038303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Salvage therapy for HIV infection].
    Salzberger B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():32-7. PubMed ID: 16385870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third line therapy options.
    Proj Inf Perspect; 1999 Apr; (27):9-11. PubMed ID: 11366743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV treatment series. Part 4 of 4. Decisions, decisions--starting or switching anti-HIV therapy.
    McGuire S
    Posit Aware; 2003; 14(3):31-6. PubMed ID: 12866490
    [No Abstract]   [Full Text] [Related]  

  • 7. Salvage therapy.
    Gulick RM
    AIDS Clin Care; 1999 Sep; 11(9):71-3, 77-8. PubMed ID: 11366502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
    HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term suppression of HIV infection: benefits and limitations of current treatment options.
    Sension MG
    J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Salvage therapy in HIV infection].
    Salzberger B
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():52, 54-5, 57. PubMed ID: 15373050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current concepts in antiretroviral therapy failure.
    del Rio C
    Top HIV Med; 2006; 14(3):102-6. PubMed ID: 16946454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
    Torti C; Quiros-Roldan E; Regazzi M; De Luca A; Mazzotta F; Antinori A; Ladisa N; Micheli V; Orani A; Patroni A; Villani P; Lo Caputo S; Moretti F; Di Giambenedetto S; Castelnuovo F; Maggi P; Tinelli C; Carosi G;
    Clin Infect Dis; 2005 Jun; 40(12):1828-36. PubMed ID: 15909273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count.
    Jaafar A; Massip P; Sandres-Sauné K; Souyris C; Pasquier C; Aquilina C; Izopet J
    J Med Virol; 2004 Sep; 74(1):8-15. PubMed ID: 15258962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage therapy.
    Collins S
    BETA; 2003; 15(4):17-28. PubMed ID: 12691034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.
    Larru B; de Mendoza C; Bellón JM; de José MI; Mellado MJ; Soriano V; Muñoz-Fernandez MA; Ramos JT
    BMC Infect Dis; 2007 Jun; 7():55. PubMed ID: 17559687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.